NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cellbricks Therapeutics

Cellbricks Therapeutics

Private
BerlinHealthcare & Life Scienceshttps://cellbricks-therapeutics.com/

Last Round

Seed

Mar 25, 2026

Total Funding Raised

$10.07M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Cellbricks Therapeutics is a biotechnology company that develops biofabricated human tissue implants for regenerative medicine, reconstructive surgery, and wound healing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, 3D Printing, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

3D bioprintingtissue engineeringregenerative medicinevascularized tissuebiofabricationbiotechbioprinted organsorgan-on-a-chipbiomaterialstissue modelingmedical devicesAI-driven biologypreclinical researchbiotech servicessynthetic biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cellbricks Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Cellbricks Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cellbricks Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 25, 2026
SeedSep 5, 2019

Key People

Founding team and executive leadership

Tobias Lam

CTO, Head Of Technology, co-founder

Founding Team

Alexander Leutner

CEO

Executive Team

Simon MacKenzie

Chief Executive Officer

Executive Team

Cellbricks Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 25, 2026

    $10M raised in Seed round.

Cellbricks Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cellbricks Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cellbricks Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBerlin
Employee Range29
Year FoundedN/A
Last FundingMar 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.